The Global Isoniazid APIs Market was valued at USD 20.9 Million in 2024 and is projected to reach USD 35.7 Million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 8.2% during the forecast period (2024–2032). This growth is being driven by rising global tuberculosis prevalence, expanding government initiatives for TB elimination, and increasing demand for high-quality APIs in combination therapies across developing and emerging economies.

As the pharmaceutical industry intensifies efforts to combat infectious diseases like tuberculosis, the focus turns to key API manufacturers who are advancing production capabilities, ensuring regulatory compliance, and enhancing supply chains for essential anti-TB medications. In this blog, we profile the Top 10 Companies in the Isoniazid APIs Industry—a mix of established pharmaceutical giants, regional specialists, and innovation leaders shaping the future of TB treatment worldwide.

---

🔟 1. Suzhou Fifth Pharmaceutical Factory Co.

Headquarters: Suzhou, China
Key Offering: Isoniazid API (Purity min 98% and 99%), pharmaceutical intermediates

Suzhou Fifth Pharmaceutical Factory Co. stands as a prominent player in the Isoniazid API market, specializing in high-volume production for global TB treatment programs. With decades of experience in anti-infective APIs, the company supplies pharmaceutical manufacturers serving high-burden regions in Asia and Africa. Their facilities adhere to strict GMP standards, enabling reliable supply to institutional buyers and generic drug producers worldwide. Recent upgrades have focused on process optimization to improve yield and reduce impurities, meeting the demands of modern pharmacopeial requirements.

Strategic Initiatives:

• Expansion of GMP-certified production lines
• Partnerships with WHO-prequalified suppliers
• Investment in advanced purification technologies

Download FREE Sample Report: Isoniazid APIs Market – View in Detailed Research Report

---

9️⃣ 2. Shanghai New Asia Pharmaceutical Co. Ltd.

Headquarters: Shanghai, China
Key Offering: Isoniazid API (min 99% purity), anti-TB formulations

Shanghai New Asia Pharmaceutical Co. Ltd. is a key supplier of Isoniazid APIs, catering to both domestic and international markets with a focus on quality consistency. The company supports combination therapy production, providing APIs compatible with rifampicin and pyrazinamide blends. Operating multiple facilities in China, they emphasize cost-effective manufacturing while maintaining compliance with international standards, making them a preferred partner for emerging market pharmaceutical firms.

Strategic Initiatives:

• Enhancement of analytical testing capabilities
• Supply chain collaborations for TB programs
• R&D for stable API variants

---

8️⃣ 3. YUKI GOSEI KOGYO CO.,LTD

Headquarters: Tokyo, Japan
Key Offering: High-purity Isoniazid API (min 99%), custom synthesis

YUKI GOSEI KOGYO CO.,LTD excels in producing premium-grade Isoniazid APIs for regulated markets in Japan, Europe, and North America. Known for their expertise in fine chemical synthesis, the company delivers APIs with exceptional purity levels suitable for advanced formulations. Their rigorous quality control processes ensure compliance with JP pharmacopeia and other global standards, positioning them as a trusted source for high-end TB preventive therapies.

Strategic Initiatives:

• Advanced continuous flow manufacturing
• Certifications for multiple pharmacopeias
• Focus on preventive therapy applications

---

7️⃣ 4. Anuh Pharma Ltd.

Headquarters: Mumbai, India
Key Offering: Isoniazid API (min 98-99% purity), TB drug intermediates

Anuh Pharma Ltd. has strengthened its global presence through recent EU-GMP certification, enabling entry into regulated European markets. As a major Indian producer, they supply Isoniazid APIs to numerous generic manufacturers supporting national TB control programs. Their vertical integration from synthesis to final purification supports efficient scaling to meet surging demand from high-burden countries.

Strategic Initiatives:

• Acquisition of EU-GMP certification
• Capacity expansion for combination APIs
• Alliances with international procurement agencies

Download FREE Sample Report: Isoniazid APIs Market – View in Detailed Research Report

---

6️⃣ 5. Calyx Chemicals and Pharmaceuticals Ltd.

Headquarters: Mumbai, India
Key Offering: Isoniazid API (min 98% purity), dedicated production lines

Calyx Chemicals and Pharmaceuticals Ltd. commissioned a new dedicated Isoniazid production line in 2023, boosting annual capacity by 200 metric tons. This expansion underscores their commitment to meeting global demand for affordable, high-quality APIs. Serving pharmaceutical companies and contract manufacturers, they play a crucial role in supplying TB-endemic regions through reliable logistics networks.

Strategic Initiatives:

• New production line commissioning
• 200 MT capacity increase
• Focus on cost-effective high-purity grades

---

5️⃣ 6. Tianjin Handewei Pharmaceutical Co.,Ltd

Headquarters: Tianjin, China
Key Offering: Ultra-high purity Isoniazid API (99.5%), crystallization expertise

Tianjin Handewei Pharmaceutical Co.,Ltd has solidified its market position through technological upgrades in crystallization, achieving 99.5% purity levels that satisfy stringent pharmacopeial standards. Their innovations support advanced TB regimens, including fixed-dose combinations, and they actively supply international tenders for essential medicines.

Strategic Initiatives:

• Crystallization process upgrades
• 99.5% purity achievement
• Participation in global TB supply initiatives

---

4️⃣ 7. Amsal Chem Private Limited

Headquarters: Hyderabad, India
Key Offering: Isoniazid API (min 98% purity), WHO-prequalified

Amsal Chem Private Limited, holding significant market share alongside leading peers, leverages vertical integration for efficient API-to-formulation supply. Their WHO-prequalified facilities cater to institutional buyers like the Global Drug Facility, ensuring steady supply for national TB programs worldwide.

Strategic Initiatives:

• WHO prequalification maintenance
• Vertical integration strategies
• Service to high-volume GDF buyers

---

3️⃣ 8. China Res Double-Crane Pharmaceutical

Headquarters: Beijing, China
Key Offering: Comprehensive Isoniazid API portfolio, combination support

China Res Double-Crane Pharmaceutical commands substantial market share through robust production and quality systems. They invest heavily in facilities for institutional demand, supporting global TB eradication with reliable, pharmacopeia-compliant APIs.

Strategic Initiatives:

• Major market share leadership
• Investments in prequalified production
• Broad supply to TB programs

---

2️⃣ 9. Hetero Drugs Limited

Headquarters: Hyderabad, India
Key Offering: Isoniazid API (min 99% purity), anti-TB APIs

Hetero Drugs Limited is a vital contributor to the Isoniazid API ecosystem, producing for generic TB drugs used in PEPFAR and other initiatives. Their large-scale facilities ensure competitive pricing and consistent quality for public health markets.

Strategic Initiatives:

• Support for PEPFAR programs
• Large-scale API production
• Quality enhancements for tenders

---

1️⃣ 10. Macleods Pharmaceuticals Ltd.

Headquarters: Mumbai, India
Key Offering: Isoniazid API supply, finished TB formulations

Macleods Pharmaceuticals Ltd. leads the Isoniazid APIs market with integrated operations from API to finished doses. They partner with global health organizations, delivering WHO-prequalified products to combat TB in high-burden areas effectively.

Strategic Initiatives:

• Integrated API-to-formulation model
• Global health partnerships
• Consistent supply for eradication efforts

Read Full Report: Isoniazid APIs Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Isoniazid APIs Is Accessible, High-Quality, and Innovative

The Isoniazid APIs market is evolving rapidly amid persistent TB challenges. While standard purity grades dominate volume, investments surge in higher-purity variants, process innovations, and resilient supply chains to address resistance and access issues.

📈 Key Trends Shaping the Market:

• Rapid production capacity expansion in Asia-Pacific, Europe, and emerging regions
• Regulatory tightening for cGMP and pharmacopeial compliance by 2030
• Technological advancements like continuous flow chemistry and green processes
• Strategic alliances between API makers, pharma firms, and global health programs

Read Full Report: Isoniazid APIs Market – View in Detailed Research Report

The companies listed above are not only supplying critical APIs—they’re spearheading the global fight against tuberculosis.